BNP/CALL/ELI LILLY & CO/750/0.1/17.01.25 | Market Closed - Boerse Frankfurt Warrants 01:20:43 12/07/2024 am IST | ||
| 20.59 EUR | -2.65% |
|
| Current month | +6.67% | ||
| 1 month | +27.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 11/24/11 | 20.14 | -4.78% |
| 10/24/10 | 21.15 | +2.72% |
| 09/24/09 | 20.59 | +6.63% |
| 08/24/08 | 19.31 | +1.10% |
| 05/24/05 | 19.1 | +5.12% |
Real-time Boerse Frankfurt Warrants
Last update July 12, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC36T0 |
| ISIN | DE000PC36T06 |
| Date issued | 30/01/2024 |
| Strike | 750 $ |
| Maturity | 17/01/2025 (190 Days) |
| Parity | 10 : 1 |
| Emission price | 3.63 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.55 € |
|---|---|
| Lowest since issue | 4.44 € |
| Spread | 0.02 € |
| Spread % | 0.10% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
887.2
USD
Spread / Average Target
-5.03%
- Stock Market
- Warrants
- Warrant
